SCHEMBL25840772

SCHEMBL25840772

Cc1ccc(NC(=S)NCS(=O)(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.58
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
HTT P42858 1/20 0.51
GAA P10253 3/20 0.50
HPGD P15428 1/20 0.50
ALDH1A1 P00352 2/20 0.49
PTGS2 P35354 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 1/20 0.49
ALOX12 P18054 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25840779 0.85 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4
SCHEMBL25840781 0.84 RECQL (0.56) SMN1; SMN2MEN1KMT2AHTTHPGD
SCHEMBL25840768 0.83 NPC1 (0.60) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4
SCHEMBL25840789 0.81 POLB (0.46) ALDH1A1LMNATDP1POLB
SCHEMBL23328363 0.79 CDK1 (0.63) SMN1; SMN2MEN1KMT2AHTTGAA
SCHEMBL21319443 0.78 SMN1; SMN2 (0.66) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4
SCHEMBL5455321 0.78 SMN1; SMN2 (0.66) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4
SCHEMBL29043442 0.78 RECQL (0.53) SMN1; SMN2MEN1KMT2AHTTHPGD
SCHEMBL1276739 0.77 KMT2A (0.79) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4
SCHEMBL25840794 0.76 ABAT (0.72) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701333-B2 Antibacterial compounds Kent Innovation & Enterprise (GB) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701333-B2 Antibacterial compounds ARF1, ARL1, TLR1 SMN1; SMN2 3087/4885MEN1 1300/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.